Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1. The Company is seeking the regulatory approval and commercialization of its lead drug candidate, selinexor (KPT-330), as a single orally administered agent in cancer indications with unmet clinical need, initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.
Company Growth (employees)
Newton, US
Size (employees)
105 (est)
Karyopharm Therapeutics was founded in 2008 and is headquartered in Newton, US

Key People at Karyopharm Therapeutics

Michael Kauffman

Michael Kauffman

Chief Executive Officer &Board of Directors
John McCartney

John McCartney

Senior Director, Product Leadership
Brian Austad

Brian Austad

Vice President, Head of Pharmaceutical Sciences
Dilara McCauley

Dilara McCauley

Vice President, Product Leadership

Karyopharm Therapeutics Office Locations

Karyopharm Therapeutics has offices in Newton, München
Newton, US (HQ)
85 Wells Ave
München, DE
9 Franziska-Bilek-Weg

Karyopharm Therapeutics Metrics

Karyopharm Therapeutics Financial Metrics

Revenue (2015)

$250 k

Revenue growth (2014-15), %


Net income (2015)

($118.2 m)

Market capitalization (21-Mar-2017)

$428.5 m

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$49.7 m
Karyopharm Therapeutics's current market capitalization is $428.5 m.
Karyopharm Therapeutics's revenue was reported to be $250 k in FY, 2015 which is a 9.2% increase from the previous period.
FY, 2013FY, 2014FY, 2015


$387 k$229 k$250 k

Revenue growth, %


R&D expense

$28.5 m$60.1 m$97.7 m

General and administrative expense

$5.9 m$15.9 m$21.6 m

Operating expense total

$34.3 m$76.1 m$119.3 m


($34 m)($75.8 m)($119.1 m)

EBIT margin, %


Interest expense

$1 k

Interest income

$3 k$97 k$897 k

Net Income

($33.9 m)($75.8 m)($118.2 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$156 m$150.6 m$58.4 m$49.7 m

Accounts Receivable


$2 m$2 m$2 m$2.1 m

Current Assets

$158 m$207.8 m$177.6 m$131.6 m


$240 k$2.8 m$3.5 m$2.8 m

Total Assets

$158.2 m$220.3 m$215.4 m$180.4 m

Accounts Payable

$1.7 m$6.3 m$3.8 m$4.8 m

Current Liabilities

$3.3 m$12.3 m$15.1 m$16.5 m

Additional Paid-in Capital

$217.5 m$345.2 m$455.2 m$528.6 m

Retained Earnings

($138.3 m)($256.5 m)($366.1 m)

Total Equity

$154.9 m$206.8 m$198.4 m$162.2 m

Financial Leverage

1 x1.1 x1.1 x1.1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($33.9 m)($75.8 m)($118.2 m)($109.6 m)

Depreciation and Amortization

$144 k$323 k$634 k$717 k

Accounts Receivable


($1.4 m)($45 k)($55 k)($120 k)

Accounts Payable

$664 k$4.5 m($2.4 m)$945 k

Cash From Operating Activities

($30.3 m)($51.4 m)($94 m)($84.4 m)

Purchases of PP&E

($57 k)($2.8 m)($1.4 m)($70 k)

Cash From Investing Activities

($57 k)($67 m)($90.8 m)$24.6 m

Cash From Financing Activities

$185.9 m$113.1 m$92.7 m$51.2 m

Karyopharm Therapeutics Operating Metrics

Karyopharm Therapeutics's Patents Granted was reported to be 10 in FY, 2015
FY, 2015

Patents Granted


Karyopharm Therapeutics Market Value History

Karyopharm Therapeutics Online Presence

Karyopharm Therapeutics News

Karyopharm Therapeutics Company Life

You may also be interested in